Skip to main content
Log in

Barnidipine

A Viewpoint by Takao Saruta

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Teramura T, Watanabe T, Higuchi S, et al. Metabolism and pharmacokinetics of barnidipine hydrochloride, a calcium channel blocker, in man following oral administration of its sustained release formulation. Xenobiotica 1997 Feb; 27(2): 203–16

    Article  PubMed  CAS  Google Scholar 

  2. Yoshinaga K, Iimura O, Abe K, et al. Clinical effects of YM730 (mepirodipine hydrochloride) on essential hypertension. Multicenter open trial by monotherapy and concomitant therapy. Pharmacotherapy Ther 1990; 18: 3103–20

    Google Scholar 

  3. Yoshinaga K, Iimura O, Abe K, et al. Clinical evaluation of YM730 (mepirodipine hydrochloride) in the treatment of essential hypertension. A double-blind comparative clinical trial with a sustained-release preparation of nicardipine hydrochloride as a control Igaku no Ayumi 1991; 156: 543–60

    Google Scholar 

  4. Imai Y, Abe K, Nishiyama A, et al. Evaluation of the antihypertensive effect of barnidipine, a dihydropyridine calcium entry blocker, as determined by the ambulatory blood pressure level averaged for 24 h, daytime, and nighttime. Barnidipine Study Group. Am J Hypertens 1997 Dec; 10 (12 Pt 1): 1415–9

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saruta, T. Barnidipine. Drugs 61, 997–998 (2001). https://doi.org/10.2165/00003495-200161070-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161070-00009

Navigation